Avalo Therapeutics, Inc. (AVTX) Operating margin 2016–2025
Avalo Therapeutics, Inc. (AVTX) operating margin by fiscal year — reported operating income divided by reported revenue.
-123601.7%FY2025 · since FY2016: -1394.6% → -123601.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -123601.7% | -108066.1 pp |
| FY2024 | -15535.6% | -14114.0 pp |
| FY2023 | -1421.6% | -1214.2 pp |
| FY2022 | -207.4% | +1314.2 pp |
| FY2021 | -1521.6% | -434.2 pp |
| FY2020 | -1087.4% | -848.3 pp |
| FY2019 | -239.1% | +264.3 pp |
| FY2018 | -503.4% | -553.3 pp |
| FY2017 | 49.9% | +1444.6 pp |
| FY2016 | -1394.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice